TY - JOUR
TI - The present and future disease burden of hepatitis C virus (HCV)
infections with today's treatment paradigm - volume 2
AU - Hatzakis, A.
AU - Chulanov, V.
AU - Gadano, A. C.
AU - Bergin, C. and
AU - Ben-Ari, Z.
AU - Mossong, J.
AU - Schreter, I.
AU - Baatarkhuu, O. and
AU - Acharya, S.
AU - Aho, I.
AU - Anand, A. C.
AU - Andersson, M. I. and
AU - Arendt, V.
AU - Arkkila, P.
AU - Barclay, K.
AU - Bessone, F.
AU - Blach, S.
AU - and Blokhina, N.
AU - Brunton, C. R.
AU - Choudhuri, G.
AU - Cisneros, L.
AU - and Croes, E. A.
AU - Dahgwahdorj, Y. A.
AU - Dalgard, O.
AU - Daruich, J.
AU - R.
AU - Dashdorj, N. R.
AU - Davaadorj, D.
AU - de Knegt, R. J.
AU - de
AU - Vree, M.
AU - Estes, C.
AU - Flisiak, R.
AU - Gane, E.
AU - Gower, E. and
AU - Halota, W.
AU - Henderson, C.
AU - Hoffmann, P.
AU - Hornell, J. and
AU - Houlihan, D.
AU - Hrusovsky, S.
AU - Jarcuska, P.
AU - Kershenobich, D. and
AU - Kostrzewska, K.
AU - Kristian, P.
AU - Leshno, M.
AU - Lurie, Y. and
AU - Mahomed, A.
AU - Mamonova, N.
AU - Mendez-Sanchez, N.
AU - Norris, S. and
AU - Nurmukhametova, E.
AU - Nymadawa, P.
AU - Oltman, M.
AU - Oyunbileg, J. and
AU - Oyunsuren, Ts.
AU - Papatheodoridis, G.
AU - Pimenov, N. and
AU - Prabdial-Sing, N.
AU - Prins, M.
AU - Radke, S.
AU - Rakhmanova, A. and
AU - Razavi-Shearer, K.
AU - Reesink, H. W.
AU - Ridruejo, E.
AU - Safadi, R.
AU - and Sagalova, O.
AU - Sanchez Avila, J. F.
AU - Sanduijav, R. and
AU - Saraswat, V.
AU - Seguin-Devaux, C.
AU - Shah, S. R.
AU - Shestakova, I.
AU - and Shevaldin, A.
AU - Shibolet, O.
AU - Silva, M. O.
AU - Sokolov, S. and
AU - Sonderup, M.
AU - Souliotis, K.
AU - Spearman, C. W.
AU - Staub, T. and
AU - Stedman, C.
AU - Strebkova, E. A.
AU - Struck, D.
AU - Sypsa, V. and
AU - Tomasiewicz, K.
AU - Undram, L.
AU - van der Meer, A. J.
AU - van Santen,
AU - D.
AU - Veldhuijzen, I.
AU - Villamil, F. G.
AU - Willemse, S. and
AU - Zuckerman, E.
AU - Zuure, F. R.
AU - Puri, P.
AU - Razavi, H.
JO - Journal of Viral Hepatitis
PY - 2015
VL - 22
TODO - 1
SP - 26-45
PB - Wiley
SN - 1352-0504, 1365-2893
TODO - 10.1111/jvh.12351
TODO - diagnosis; disease burden; epidemiology; HCV; hepatitis C; incidence;
mortality; prevalence; treatment
TODO - Morbidity and mortality attributable to chronic hepatitis C virus (HCV)
infection are increasing in many countries as the infected population
ages. Models were developed for 15 countries to quantify and
characterize the viremic population, as well as estimate the number of
new infections and HCV related deaths from 2013 to 2030. Expert
consensus was used to determine current treatment levels and outcomes in
each country. In most countries, viremic prevalence has already peaked.
In every country studied, prevalence begins to decline before 2030, when
current treatment levels were held constant. In contrast, cases of
advanced liver disease and liver related deaths will continue to
increase through 2030 in most countries. The current treatment paradigm
is inadequate if large reductions in HCV related morbidity and mortality
are to be achieved.
ER -